共被期刊论文引用了3次
您的检索式：您选中1篇文献正在查看引证文献汇总
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Role of cetuximab in first-line treatment of metastatic colorectal cancer显示文摘The treatment of metastatic colorectal cancer(mCRC)has evolved considerably in the last decade,currently allowing most mCRC patients to live more than two years.Monoclonal antibodies targeting the epidermal growth factor receptor(EGFR)and vascular endothelial growth factor play an important role in the current treatment of these patients.However,only antibodies directed against EGFR have a predictive marker of response,which is the mutation status of v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog(KRAS).Cetuximab has been shown to be effective in patients with KRAS wild-type mCRC.The CRYSTAL study showed that adding cetuximab to FOLFIRI(regimen of irinotecan,infusional fluorouracil and leucovorin)significantly improved results in the first-line treatment of KRAS wildtype mCRC.However,results that evaluate the efficacy of cetuximab in combination with oxaliplatin-based chemotherapy in this setting are contradictory.On the other hand,recent advances in the management of colorectal liver metastases have improved survival in these patients.Adding cetuximab to standard chemotherapy increases the response rate in patients with wild-type KRAS and can thus increase the resectability rate of liver metastases in this group of patients.In this paper we review the different studies assessing the efficacy of cetuximab in the first-line treatment of mCRC. | Miguel Jhonatan Sotelo Beatriz García-Paredes Carlos Aguado Javier Sastre Eduardo Díaz-Rubio | 2014 | World Journal of Gastroenterology2014，20，15： | 7 |
| 2 | Beyond KRAS:Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer显示文摘Systematic analysis of the epidermal growth factor receptor(EGFR)pathway revealed that biomarkers could be used to predict the response to and outcome of antiEGFR therapies in patients affected by metastatic colorectal cancer.We have conducted a review on the most recent findings and advances on this topic.To this aim,we searched the PubMed database for articles devoted to predictive and prognostic biomarkers for patients administered cetuximab-and panitumumab-based therapies.Here we review the state of the art and the controversies about the molecular factors known to be predictors of the efficacy of anti-EGFR therapy,namely,KRAS,BRAF,NRAS,PI3KCA and PTEN,and we discuss their prognostic value in colorectal cancer patients. | Alfonso De Stefano Chiara Carlomagno | 2014 | World Journal of Gastroenterology2014，20，29： | 2 |
| 3 | How to select the optimal treatment for first line metastatic colorectal cancer显示文摘Choice of first line treatment for patients with metastatic colorectal cancer(mCRC)is based on tumour and patient related factors and molecular information for determination of individual treatment aim and thus treatment intensity.Recent advances(e.g.,extended RAS testing)enable tailored patient assignment to the most beneficial treatment approach.Besides fluoropyrimidines,irinotecan and oxaliplatin,a broad variety of molecular targeting agents are currently available,e.g.,anti-angiogenic agents(bevacizumab)and epidermal growth factor receptor(EGFR)antibodies(cetuximab,panitumumab)for first line treatment of mCRC.Although some combinations should be avoided(e.g.,oral or bolus fluoropyrimidines,oxaliplatin and EGFR antibodies),treatment options range from single agent to highly effective four-drug regimen.Preliminary data comparing EGFR antibodies and bevacizumab,both with chemotherapy,seem to favour EGFR antibodies in RAS wildtype disease.However,choosing the most appropriate treatment approach for mCRC patients remains a complex issue,with numerous open questions. | Alexander Stein Carsten Bokemeyer | 2014 | World Journal of Gastroenterology2014，20，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员